Takeda and Endo hit with pay-for-delay claims
Shutterstock/Michael Vi
Takeda Pharmaceutical and Endo International are facing a lawsuit over an alleged scheme to block generic competition to Takeda’s branded anti-constipation drug Amitiza.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10